CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancer.
Rajamanickam V., Simons ND., Rosales W., Kravchenko A., Yamazaki T., Bernard B., Piening B., Domingo E., Maughan T., Alvarez-Jimenez C., Desilvio T., Viswanath S., Whiteford M., Hayman A., O'Brien D., Kiely MX., Ahmad R., Gough MJ., Crittenden MR., Young KH.
Improving responses to neoadjuvant therapy for patients with locally advanced rectal cancer has the potential to improve organ preservation and disease-free survival. Knowing which patients may need therapeutic escalation or de-escalation from standard-of-care treatment remains an area of investigation. We previously reported the primary and secondary endpoints of our single-arm study combining transforming growth factor beta receptor inhibitor, Galunisertib, with neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Here we analyze RNA sequencing data obtained from tissue biopsies at baseline and after 2 weeks of galunisertib. Differences in expression of genes associated with MYC, inflammation, and epithelial-to-mesenchymal transition were observed between complete responders (CR) and